Efficacy and Safety of Galcanezumab as a Preventive Treatment for Episodic Migraine in South Korean Patients: A Post-Hoc Analysis of a Phase 3 Clinical Trial

BACKGROUND AND PURPOSE: The estimated prevalence of migraines in South Korea is 6.0%, with affected patients having unmet needs. The efficacy, safety, and tolerability of galcanezumab, a humanized monoclonal antibody, for episodic migraine (EM) prevention was evaluated in South Korean patients. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Byung-Kun, Cho, Soo-Jin, Han, Jeong Hee, Dell’Agnello, Grazia, Panni, Tommaso, Kim, Manho, Oh, Kyungmi, Moon, Heui-Soo, Chu, Min Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471542/
https://www.ncbi.nlm.nih.gov/pubmed/37455511
http://dx.doi.org/10.3988/jcn.2022.0180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471542/
https://www.ncbi.nlm.nih.gov/pubmed/37455511
http://dx.doi.org/10.3988/jcn.2022.0180

Ejemplares similares